Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | GSK3B | P49841 | 8/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | OGG1 | O15527 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628863 | 0.81 | PTPN1 (0.59) | PTPN1GSK3BHPGDS | |
| SCHEMBL194730 | 0.72 | PTPN1 (0.53) | PTPN1GSK3BHPGDSAGTR1KDM4E | |
| SCHEMBL9472562 | 0.71 | PBRM1 (0.49) | KDM4ERAB9AMEN1KMT2ACLCN2 | |
| SCHEMBL9409754 | 0.70 | PTPN1 (0.65) | PTPN1GSK3BHPGDSKDM4EMEN1 | |
| SCHEMBL14989349 | 0.69 | THRB (0.42) | KDM4EMEN1KMT2A | |
| SCHEMBL10396219 | 0.69 | PTPN1 (0.50) | PTPN1GSK3BKDM4ERAB9AMEN1 | |
| SCHEMBL1360356 | 0.69 | GSK3B (0.46) | PTPN1GSK3BHPGDSKDM4EMEN1 | |
| SCHEMBL1002898 | 0.69 | LPAR2 (0.50) | KDM4EMEN1KMT2A | |
| SCHEMBL9732721 | 0.68 | BACE1 (0.57) | PTPN1GSK3BRAB9AMEN1KMT2A | |
| SCHEMBL7959032 | 0.67 | ALDH1A1 (0.45) | KDM4ERAB9AKMT2ACLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020219497-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3631452-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| EP-3420362-A1 | ANTIBODIES | The Binding Site Group Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3420361-A1 | MASS SPECTROMETRY KIT | The Binding Site Group Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018215768-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | THE BINDING SITE GROUP LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
| WO-2017144900-A1 | MASS SPECTROMETRY KIT | THE BINDING SITE GROUP LIMITED (GB) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144903-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2017-08-31 | — | — | WO | disclosed |
| WO-2011050342-A2 | RATIONAL DESIGN OF A BIOCOMPATIBLE SYNTHETIC LAMININ-111 POLYMER AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-2268673-A2 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2242505-A2 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | BioGeneriX AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2005012484-A2 | ANTIBODY-TOXIN CONJUGATES | NEOSE TECHNOLOGIES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004103275-A2 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | NEOSE TECHNOLOGIES, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004099231-A2 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NEOSE TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004097372-A2 | ELEMENT-CODED AFFINITY TAGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004083258-A2 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | NEOSE TECHNOLOGIES INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004065569-A2 | MULTI-FUNCTIONAL ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004033651-A2 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003031464-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1218413-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | The Regents of the University of California (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001022922-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |